Navigation Links
Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
Date:10/25/2010

VIENNA, Oct. 25 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

In the randomized, controlled Phase II clinical trial (33 sites in 8 countries), about 400 mechanically ventilated intensive care patients, who are at particular high risk of acquiring severe and often life-threatening forms of Pseudomonas aeruginosa infections, such as Ventilator-Associated Pneumonia (VAP), sepsis or soft tissue infection were vaccinated on days zero and seven in four treatment groups  receiving 100 or 200mcg alum-adjuvanted vaccine, 100mcg non-adjuvanted vaccine or alum as placebo control.

The primary endpoint of the study was met in that all vaccine groups showed good seroconversion rates (65 - 81%) with IgG antibody Geometric Mean Titers (GMTs) (995-2117 ELISA units/ml). There were no significant differences in treatment emergent adverse events between the treatment arms and local and systemic tolerability appeared to be good, as far as assessable in this study population. The number and nature of reported drug related adverse events does not raise any safety concern and has been confirmed earlier by a Data Safety Monitoring Board (DSMB) based on interim data.

Secondary immunogenicity endpoints were also met in this study and included IgG response assessed seven times over a period of 90 days, measurement of functional antibody activity by opsonophagocytosis assay, and measurement of antibody avidity.

Overall robust immunogenicity following second vaccination was observed in all vaccine groups. A dose-response could be observed, whereas alum did not show a clear immune-enhancing effect. Antibody avid
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
2. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
3. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
4. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
5. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
7. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
8. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
9. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Pranoprofen ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma ... as an inflammatory drug, pranoprofen was later developed ... under the trade name of pranopulin for the ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 2010 Genomic Health, Inc. (Nasdaq: GHDX ) today ... 30, 2010. Total revenue increased to $46.3 million in ... third quarter of 2009.  Product revenue was $45.8 million in the ... $38.9 million in the third quarter of 2009. ...
... Nov. 8, 2010 PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly dividend of $.12 per share ...  The dividend will be payable December 15, 2010, to shareholders ... public in 1984 Mesa Labs has maintained strong cash positions ...
Cached Medicine Technology:Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 8
(Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... mesothelioma develops, may extend and improve the lives of patients, according to a ... Click here to read the full article. , The authors of ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik ... zero standard shipping costs. , “Before, a threshold of $49.00 was required to qualify ... and items qualify for free standard shipping for customers regardless of the item’s selling ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... the Ganesh Shanker Vidyarthi Memorial (GSVM) Medical College have ... // in bringing medical knowledge and technology that would ... ,The two institutes have signed a memorandum ... increased collaboration on several fronts. ,The heads ...
... Association (AMA) says that the federal budget has poorly ... for not addressing problems like obesity //and indigenous health. ... develop world-first medical technologies to fight cancer and heart ... for the National Health and Medical Research Council by ...
... Japanese Encephalitis immunisation which was initially scheduled to take ... 15. //The Uttar Pradesh government is responsible for the ... dates. Japanese Encephalitis is the main reason for the ... Statistics show that in UP alone about 600-700 children ...
... of fungal infection in Bausch and Lomb lens wearers are ... association arrived at is that nearly 50% of those who ... solution, manufactured by Bausch and Lomb. ,Bausch & ... solution, feels that the cause of Fusarium keratitis infection is ...
... study, drinking tap water increases the risk of bladder cancer. ... if one drink too much of it may be a ... published in the April 15 issue of International Journal of ... based drinks each day increased the risk of bladder cancer ...
... Research (ICAR) has identified Indira Kankoda I (RMF 37), ... Chhattisgarh, Uttar Pradesh, Jharkhand, Orissa and Maharashtra. ... will be the first spine gourd variety identified for ... vegetable crop locally known as Meetha Karela, Khekhsa, Padora ...
Cached Medicine News:
... Lyphochek Fertility Control ... monitor the clinically significant ... most frequently assayed during ... Elevated hCG and hCG-Beta ...
Liquichek Spinal Fluid Control is a liquid, bilevel product designed to monitor the performance of automated and manual procedures for the analysis of proteins and other critical analytes assayed in ...
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
... Nucleic Sample Preparation Platform provides flexible, automated ... platform can prepare up to 96 patient ... and one half-hours, and performs onboard quantitation ... 30 minutes each. Based on Beckman ...
Medicine Products: